vs
Douglas Elliman Inc.（DOUG）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Douglas Elliman Inc.的季度营收约是再鼎医药的1.9倍（$245.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.9%），Douglas Elliman Inc.自由现金流更多（$-14.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.7%）
Douglas Elliman Inc.是美国领先的住宅房地产经纪企业，提供高端房产买卖、租赁、物业管理及相关咨询服务，核心业务覆盖纽约、加州、佛罗里达、得克萨斯等都会区，主要服务高净值客户群体。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
DOUG vs ZLAB — 直观对比
营收规模更大
DOUG
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出16.2%
0.9%
自由现金流更多
DOUG
多$12.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
10.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $245.4M | $127.1M |
| 净利润 | $68.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 27.3% | -54.6% |
| 净利率 | 27.9% | — |
| 营收同比 | 0.9% | 17.1% |
| 净利润同比 | 1243.4% | — |
| 每股收益（稀释后） | $0.80 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOUGZLAB
| Q4 25 | $245.4M | $127.1M | ||
| Q3 25 | $262.8M | $115.4M | ||
| Q2 25 | $271.4M | $109.1M | ||
| Q1 25 | $253.4M | $105.7M | ||
| Q4 24 | $243.3M | $108.5M | ||
| Q3 24 | $266.3M | $101.8M | ||
| Q2 24 | $285.8M | $100.1M | ||
| Q1 24 | $200.2M | $87.1M |
净利润DOUGZLAB
| Q4 25 | $68.6M | — | ||
| Q3 25 | $-24.7M | $-36.0M | ||
| Q2 25 | $-22.7M | $-40.7M | ||
| Q1 25 | $-6.0M | $-48.4M | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-27.2M | $-41.7M | ||
| Q2 24 | $-1.7M | $-80.3M | ||
| Q1 24 | $-41.5M | $-53.5M |
毛利率DOUGZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率DOUGZLAB
| Q4 25 | 27.3% | -54.6% | ||
| Q3 25 | -4.1% | -42.3% | ||
| Q2 25 | -2.0% | -50.3% | ||
| Q1 25 | -2.1% | -53.3% | ||
| Q4 24 | -6.7% | -62.6% | ||
| Q3 24 | -2.8% | -66.6% | ||
| Q2 24 | -1.3% | -76.0% | ||
| Q1 24 | -20.7% | -80.7% |
净利率DOUGZLAB
| Q4 25 | 27.9% | — | ||
| Q3 25 | -9.4% | -31.2% | ||
| Q2 25 | -8.4% | -37.3% | ||
| Q1 25 | -2.4% | -45.8% | ||
| Q4 24 | -2.5% | — | ||
| Q3 24 | -10.2% | -40.9% | ||
| Q2 24 | -0.6% | -80.2% | ||
| Q1 24 | -20.7% | -61.4% |
每股收益（稀释后）DOUGZLAB
| Q4 25 | $0.80 | $-0.05 | ||
| Q3 25 | $-0.29 | $-0.03 | ||
| Q2 25 | $-0.27 | $-0.04 | ||
| Q1 25 | $-0.07 | $-0.04 | ||
| Q4 24 | $-0.06 | $-0.09 | ||
| Q3 24 | $-0.33 | $-0.04 | ||
| Q2 24 | $-0.02 | $-0.08 | ||
| Q1 24 | $-0.50 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $115.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $183.9M | $715.5M |
| 总资产 | $444.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOUGZLAB
| Q4 25 | $115.5M | $689.6M | ||
| Q3 25 | $143.0M | $717.2M | ||
| Q2 25 | $136.3M | $732.2M | ||
| Q1 25 | $136.8M | $757.3M | ||
| Q4 24 | $145.5M | $779.7M | ||
| Q3 24 | $151.4M | $616.1M | ||
| Q2 24 | $92.9M | $630.0M | ||
| Q1 24 | $91.5M | $650.8M |
股东权益DOUGZLAB
| Q4 25 | $183.9M | $715.5M | ||
| Q3 25 | $115.1M | $759.9M | ||
| Q2 25 | $137.6M | $791.7M | ||
| Q1 25 | $158.2M | $810.8M | ||
| Q4 24 | $162.2M | $840.9M | ||
| Q3 24 | $173.6M | $667.7M | ||
| Q2 24 | $196.9M | $704.2M | ||
| Q1 24 | $195.1M | $762.2M |
总资产DOUGZLAB
| Q4 25 | $444.4M | $1.2B | ||
| Q3 25 | $480.6M | $1.2B | ||
| Q2 25 | $489.0M | $1.2B | ||
| Q1 25 | $493.9M | $1.2B | ||
| Q4 24 | $493.9M | $1.2B | ||
| Q3 24 | $502.7M | $985.3M | ||
| Q2 24 | $463.9M | $987.4M | ||
| Q1 24 | $461.1M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | -6.0% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | -0.21× | — |
| 过去12个月自由现金流最近4个季度 | $-17.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流DOUGZLAB
| Q4 25 | $-14.4M | $-26.0M | ||
| Q3 25 | $5.5M | $-32.0M | ||
| Q2 25 | $642.0K | $-31.0M | ||
| Q1 25 | $-5.6M | $-61.7M | ||
| Q4 24 | $-9.0M | $-55.8M | ||
| Q3 24 | $9.0M | $-26.8M | ||
| Q2 24 | $1.3M | $-42.2M | ||
| Q1 24 | $-27.3M | $-90.1M |
自由现金流DOUGZLAB
| Q4 25 | $-14.7M | $-26.7M | ||
| Q3 25 | $4.7M | $-35.0M | ||
| Q2 25 | $-575.0K | $-33.9M | ||
| Q1 25 | $-6.7M | $-63.2M | ||
| Q4 24 | $-10.2M | $-58.4M | ||
| Q3 24 | $7.7M | $-28.2M | ||
| Q2 24 | $432.0K | $-42.9M | ||
| Q1 24 | $-29.4M | $-91.1M |
自由现金流率DOUGZLAB
| Q4 25 | -6.0% | -21.0% | ||
| Q3 25 | 1.8% | -30.4% | ||
| Q2 25 | -0.2% | -31.1% | ||
| Q1 25 | -2.6% | -59.9% | ||
| Q4 24 | -4.2% | -53.8% | ||
| Q3 24 | 2.9% | -27.7% | ||
| Q2 24 | 0.2% | -42.9% | ||
| Q1 24 | -14.7% | -104.5% |
资本支出强度DOUGZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 0.5% | 2.4% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 1.0% | 1.1% |
现金转化率DOUGZLAB
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
